TLSA - Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd Logo

TLSA - Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
GlobeNewswire • 3 months ago • score: 0.39
NEW YORK, June 13, 2025 ( GLOBE NEWSWIRE ) -- Tiziana Life Sciences, Ltd. ( Nasdaq: TLSA ) ( "Tiziana" or the "Company" ) , a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the UK.

52W High
$2.60
52W Low
$0.63
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.20
Valuation
As of 2023-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-5.98
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
49.28
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
43.06%
Institutions (25–75% balanced)
4.15%
Shares Outstanding
116,848,000
Float
63,394,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2023-06-30 (Overview)
Revenue (TTM)
-3,595,000
Gross Profit (TTM)
0
EPS (TTM)
-0.11
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-2.51%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.0745
Previous
-0.0711
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025